stockrow
Friday 6 November 2026
Export ZYME’s income statement to Excel — free account
Zymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
- Revenue
- −90.6%
- EPS
- −2,166.7%
- Free cash flow
- −385.5%
Quarter to June 2026, against a year earlier
29.68
0.94
+3.27%
Follow ZYME
Alert me
Zymeworks Inc. (ZYME) Revenue
Zymeworks Inc.'s revenue for fiscal 2025 was $106.0M, up 38.9% from $76.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was $37.1M. Over the past ten years it has ranged from $9.7M (fiscal 2015) to $412.5M (fiscal 2022); the current reading is higher than 91% of that period. Zymeworks Inc. ranks 145th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $106.0M | 38.87% |
| FY2024 | $76.3M | 0.38% |
| FY2023 | $76.0M | (81.57%) |
| FY2022 | $412.5M | 1,446.03% |
| FY2021 | $26.7M | (31.50%) |
| FY2020 | $39.0M | 31.84% |
| FY2019 | $29.5M | (44.28%) |
| FY2018 | $53.0M | 2.43% |
| FY2017 | $51.8M | 370.18% |
| FY2016 | $11.0M | 13.96% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $4.6M | 90.61% |
| Mar 2026 | $2.4M | (4.25%) |
| Dec 2025 | $2.5M | (90.89%) |
| Sep 2025 | $27.6M | (43.33%) |
| 38 more quarters | Free account |
Against its own ten years
Low $9.7M
High $412.5M
Ten-year median
$51.8M
Current reading's percentile
91
Revenue against peers
| Company | Revenue |
|---|---|
| BHVN Biohaven Ltd. compare | $995.4M |
| VCEL Vericel Corporation compare | $324.2M |
| AUPH Aurinia Pharmaceuticals Inc compare | $321.7M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | $282.0M |
| SEPN Septerna, Inc. compare | $98.9M |
| ZYME Zymeworks Inc. | $37.1M |
| IMNM Immunome, Inc. compare | $12.6M |
| COAG Hemab Therapeutics Holdings, Inc. compare | — |
| VERA Vera Therapeutics, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ZYME
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement